Gyros to Merge with Protein Technologies
The combined company will have more than 100 employees, according to Mr. Calvo. “Gyros Protein Technologies’ vision is to create a leading peptide/protein tools company of more than $50 million in revenue with attractive EBITDA margins, by developing market leading products, and driving above market growth rates, both through organic growth and via strategic acquisitions,” he told IBO.
Uppsala, Sweden and Tucson, AZ 3/16/16—Gyros, a Swedish provider of automated nanoliter-scale immunoassays, and Protein Technologies, a supplier of peptide synthesizers, have agreed to form Gyros Protein Technologies. “The fields of proteins and peptides have merged, and hence so have we, creating a biotherapeutics discovery-to-production offering ideally positioning us for future expansion,” commented Protein Technologies Chairman David Patteson. “The combined company has a clear business vision, strong and profitable historical growth, and an aggressive acquisition strategy going forward.” Gyros CEO Dan Calvo will become CEO of the new company. Mr. Patteson will serve as chairman. AP6, the majority shareholder in Gyros, and Ampersand Capital Partners, the majority shareholder in Protein Technologies, will become the major shareholders in the new company.
